The purpose of this study was to determine whether variations in serum muramidase (lysozyme) activity in neutropenic patients have clinical significance. The possibility of a valid relationship is based on the premise that most of the normal plasma enzyme activity is derived from the degradation of senescent neutrophils with subsequent release of enzyme from their granules(I-4). There now is abundant evidence that muramidase is found predominantly in the lysosomes of mature neutrophils and monocytes (5), and that the number of circulating mature neutrophils correlates well with serum muramidase activity(2-4). It also has been demonstrated that increased serum muramidase activity is associated with expanded total granulocyte or monocyte populations in patients with leukemia(l,3,6,7) and the probable increase in marrow granulocyte turnover in megaloblastic anemias(8). On the other hand, serum enzyme activity frequently is reduced in acute lymphocytic leukemia in relapse(7) and other conditions which appear to reduce the total body neutrophil population(l,3). These observations suggest that neutropenia due to diminished granulopoiesis may result in reduced serum muramidase activity whereas neutropenia due to accelerated granulocyte destruction may produce either a relative or absolute increase in serum enzyme activity. Preliminary observations in patients with aplastic anemia and various types of neutropenic disorders are consistent with this suggestion(3,9).
The purpose of this study was to determine whether variations in serum muramidase (lysozyme) activity in neutropenic patients have clinical significance. The possibility of a valid relationship is based on the premise that most of the normal plasma enzyme activity is derived from the degradation of senescent neutrophils with subsequent release of enzyme from their granules(I-4). There now is abundant evidence that muramidase is found predominantly in the lysosomes of mature neutrophils and monocytes (5) , and that the number of circulating mature neutrophils correlates well with serum muramidase activity (2) (3) (4) . It also has been demonstrated that increased serum muramidase activity is associated with expanded total granulocyte or monocyte populations in patients with leukemia(l, 3, 6, 7) and the probable increase in marrow granulocyte turnover in megaloblastic anemias (8) . On the other hand, serum enzyme activity frequently is reduced in acute lymphocytic leukemia in relapse (7) and other conditions which appear to reduce the total body neutrophil population(l,3). These observations suggest that neutropenia due to diminished granulopoiesis may result in reduced serum muramidase activity whereas neutropenia due to accelerated granulocyte destruction may produce either a relative or absolute increase in serum enzyme activity. Preliminary observations in patients with aplastic anemia and various types of neutropenic disorders are consistent with this suggestion (3, 9 [kg/ml ± 6.0. There were four patients in this group witli peripheral bloodl (Fig. 1, Table 2 (witlhotut monocytosis) is hiiglily significant (P < 0.001).
The overall relationship for eitlher group between sertum muramidase activity and peripheral blood neutrophil count was poor (Fig. 2) . All blut one patient with severe neutropenia, however, witli peripheral blood neutrophil counts less than 200/mm3 in association with reduced marrow granulocyte cellularity had reduced serum enzyme activity. For any given peripheral blood neutrophil count serum mtramnidlase activity was increased in patients witlh monocytosis, but no greater tlhani in some witlhout monocytosis (Fig. 2) monocytosis it is uncertain-as to whetlher the increased serum muramidase activity is primarily of neutroplhilic or monocytic origin, but the consistently higher levels of activity stuggest a major monocyte contribution. The second group consists of patients with neutropenia associated with reduced marrow myeloid cellularity wlhichi is probably a reflection of decreased total granulopoiesis. Serum muramiclase activity ustually is reduced, but may l)e in the normal range. These observations stuggest tlhat, in the absence of monocytosis, increased serum muramidase activity in patienits with neuLtropenia is related to active granulopoiesis in association witlh increasecl granulocyte destruction. Reduced serum muramidase activity is cluie to myeloid hypoproliferation resultinig in diminislhed granulocyte turnover. Redluctioni of serum nmlirami(lase activity to levels as low as 1.4-1.6 1g/ml occurrecl in patients witlh marrow myeloid hypoplasia or aplasia. This indicates that as muchi as 80%X`of serum miuramidase activity is derive(d from degrade(d granulocytes.
The "murami(lase in(lex" lhas provedl of rather limited value in characterizing the type of neutropenia in this group of patients (7, 8 The close correlation between serum muramidase and bone marrow granulocyte activity in neutropenic patients may provide another useful parameter for the laboratory study of the mechanism of neutropenia in some patients. Decreased serum muramidase activity invariably reflects decreased neutrophil prodtuction. Increased serum muramidase in the absence of azotemia reflects either increased neutrophil turnover or monocytosis. Serum muramidase activity in the control range adds little information of value to the study of these. The eventual clinical usefulness of these relationships in the diagnosis and management of neutropenic patients, however, is uncertain at this time due to overlapping of values in some instances and minimal change in others.
SUMMARY
Serum muramidase activity was related to bone marrow and peripheral blood clhanges in 55 patients with various types of neutropenia. Normal or reduced serum enzyme activity was observed in all patients with diminished bone marrow granulocyte cellularity. Patients with neutropenia associated with abundant bone marrow granulocytes generally had normal or increased serum muramidase activity.
